Investigation of glucose-modifed liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 163-175

  Xie, Fulan ^a   Yao, Nian ^a   Qin, Yao ^a   Zhang, Qianyu ^a   Chen, Huali ^a   Yuan, Mingqing ^a   Tang, Jie ^a   Li, Xiankun ^a   Fan, Wei ^a   Zhang, Qiang ^b   Wu, Yong ^a   Hai, Li ^a   He, Qin ^a  

^a SICHUAN UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

BBB; Brain targeted; Glucose; Liposome; Polyethylene glycols

Indexed keywords

CHOLESTEROL; COUMARIN; GLUCOSE DERIVATIVE; LIPOSOME; MACROGOL; MACROGOL 1000; MACROGOL 200; MACROGOL 20000; MACROGOL 400; PHOSPHOLIPID; UNCLASSIFIED DRUG; COUMARIN 6; COUMARIN DERIVATIVE; GLUCOSE; MACROGOL DERIVATIVE; THIAZOLE DERIVATIVE; GLYCOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; EX VIVO STUDY; FILM; FLUORESCENCE IMAGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEARINFRARED FLUORESCENCE IMAGING; NONHUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; ULTRASOUND; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; BRAIN LEVEL; CHEMISTRY; METABOLISM; METHODOLOGY; NEAR INFRARED SPECTROSCOPY; TISSUE DISTRIBUTION; FLUORESCENCE ANALYSIS; GLUCONEOGENESIS; GLUCOSE ASSAY; LIPOSOMAL DELIVERY; RESIDUE ANALYSIS; STRUCTURE ANALYSIS;

MUS;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; COUMARINS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; GLUCOSE; LIPOSOMES; MICE; POLYETHYLENE GLYCOLS; SPECTROSCOPY, NEAR-INFRARED; THIAZOLES; TISSUE DISTRIBUTION;

EID: 84863081080     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/ijn.s23771     Document Type: Article

References (44)

1. Pardridge WM. Blood-brain barrier biology and methodology. J Neuroviro. 1999;5(6):556-569.
2. Pardridge WM. Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems. Int Congr. 2005;1277:49-62.
3. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci. 1999;22:11-28.
4. Cardoso FL, Brites D, Brito MA. Looking at the blood-brain barrier: Molecular anatomy and possible investigation approaches. Brain Res Rev. 2010;64(2):328-363.
5. Begley DJ, Brightman M W. Structural and functional aspects of the blood-brain barrier. Prog Drug Res. 2003;61:41-78.
6. Polt R, Porreca F, Szabo LZ, et al. Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood-brain barrier. Proc Natl Acad Sci U S A. 1994;91(15):7114-7118.
7. Halmos T, Santarromana M, Antonakis K, Scherman D. Synthesis of O-methylsulfonyl derivatives of D-glucose as potential alkylating agents for targeted drug delivery to the brain. Evaluation of their interaction with the human erythrocyte GLUT1 hexose transporter. Carbohydr Res. 1997;299(1-2):15-21.
8. Zhang ZR, Luo WZ, Nagai T. Studies on hydrolysis kinetics and photolysis kinetics of N1-retinoyl-5-fuorouracil. STP Pharma Sci. 2001;11(3): 243-246.
9. Bonina F P, Arenare L, Ippolito R, et al. Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs. Int J Pharm. 2000;202(1-2):79-88.
10. Huang DW, Shen SC, Wu JS. Effects of caffeic acid and cinnamic acid on glucose uptake in insulin-resistant mouse hepatocytes. J Agrc Food Chem. 2009;57(17):7687-7692.
11. Gould G W, Holman GD. The glucose transporter family: structure, function and tissue-specifc expression. Biochem J. 1993;295(2):329-341.
12. Schubert D. Glucose metabolism and Alzheimer's disease. Ageing Res Rev. 2005;4(2):240-257.
13. Qutub AA, Hunt CA. Glucose transport to the brain: a systems model. Brain Res Rev. 2005;49(3):595-617.
14. Dwyer DS, Vannucci SJ, Simpson IA. Expression, regulation, and functional role of glucose transporters (GLUTs) in brain. Int Rev Neurobiol. 2002;51:159-188.
15. Regina A, Roux F, Revest PA. Glucose transport in immortalized rat brain capillary endothelial cells in vitro: transport activity and GLUT1 expression. Biochim Biophys Acta. 1997;1335(1-2):135-143.
16. McAllister MS, Krizanac-Bengez L, Macchia F, et al. Mechanisms of glucose transport at the blood-brain barrier: an in vitro study. Brain Res. 2001;904(1):20-30.
17. Vakil R, Kwon GS. PEG-phospholipid micelles for the delivery of amphotericin B. J Control Release. 2005;101(1-3):386-389.
18. Torchilin V P, Trubetskoy VS, Whiteman KR, et al. New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J Pharm Sci. 1995;84(9):1049-1053.
19. Yamamoto Y, Nagasaki Y, Kato Y, et al. Long-circulating poly (ethylene glycol)-poly (D,L-lactide) block copolymer micelles with modulated surface charge. J Control Release. 2001;77(1-2):27-38.
20. Qin Y, Fan W, Chen H, et al. In vitro and in vivo investigation of Glucose-mediated brain-targeting liposomes. J Drug Target. 2010;18(7):536-549.
21. Lei F, Fan W, Li XK, et al. Design, synthesis and preliminary bio-evaluation of glucose-cholesterol derivatives as ligands for brain targeting liposomes. Chinese Chem Lett. 2011;22(7):831-834.
22. Zhao XB, Muthusamy N, Byrd JC, et al. Erratum: Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor-targeted liposomes. J Pharm Sci. 2007;96(9):2424-2439.
23. Lu W, Tan YZ, Hu KL, et al. Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier. Int J Pharm. 2005;295(1-2):247-260.
24. Lu W, Zhang Y, Tan YZ, et al. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release. 2005;107(3):428-448.
25. Demeuse P, Kerkhofs A, Struys-Ponsar C, et al. Compartmentalized coculture of rat brain endothelial cells and astrocytes: a syngenic model to study the blood-brain barrier. J Neurosci Methods. 2002; 121(1):21-31.
26. Hayashi Y, Nomura M, Yamagishi S, et al. Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia. 1997;19(1):13-26.
27. Zhang Y, Schlachetzki F, Zhang YF, et al. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specifc promoter. Hum Gene Ther. 2004;15(4):339-350.
28. Ripolles T, Agramunt M, Martinez MJ, et al. The role of ultrasound in the diagnosis, management and evolutive prognosis of acute left-sided colonic diverticulitis: a review of 208 patients. Eur Radiol. 2003;13(12):2587-2595.
29. Frangioni J V. In vivo near-infrared fuorescence imaging. Curr Opin Chem Biol. 2003;7(5):626-634.
30. Xu RX, Young DC, Mao JJ, Povoski S P. A prospective pilot clinical trial evaluating the utility of a dynamic near-infrared imaging device for characterizing suspicious breast lesions. Breast Cancer Res. 2007;9(6):R88.
31. Tromberg BJ, Pogue B W, Paulsen KD, et al. Assessing the future of diffuse optical imaging technologies for breast cancer management. Med Phys. 2008;35(6):2443-2451.
32. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3(2):90-105.
33. Cruz LJ, Tacken PJ, Fokkink R, Figdor CG. The infuence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials. 2011;32(28):6791-6803.
34. Manjappa AS, Chaudhari KR, Venkataraju M P, et al. Antibody deriva-tization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release. 2011;150(1):2-22.
35. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature. 1996;380(6574):561-562.
36. Han HD, Lee A, Song CK, et al. In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes. Int J Pharm. 2006;313(1-2):181-188.
37. Kaur I P, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nano-particles in brain targeting. J Control Release. 2008;127(2):97-109.
38. Du J, Lu WL, Ying X, et al. Dual-targeting topotecan liposomes modi-fed with tamoxifen and wheat germ agglutinin signifcantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm. 2009;6(3):905-917.
39. Shimada K, Kamps JA, Regts J, et al. Biodistribution of liposomes containing synthetic galactose-terminated diacylglyceryl-poly(ethyleneglycol)s. Biochim Biophys Acta. 1997;1326(2):329-341.
40. Costanzo PJ, Dan N, Lancaster KS, et al. Effect of changing polymer chain length on the target-mediated agglutination of polymer-grafted nanoparticles. Macromolecules. 2008;41(4):1570-1576.
41. Maeda N, Takeuchi Y, Takada M, et al. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release. 2004;100(1):41-52.
42. Pietkiewicz J, Zielinska K, Saczko J, et al. New approach to hydro-phobic cyanine-type photosensitizer delivery using polymeric oil-cored nanocarriers: Hemolytic activity, in vitro cytotoxicity and localization in cancer cells. Eur J Pharm Sci. 2010;39(5):322-325.
43. Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic effcacy of brain glioma in animals. J Control Release. 2010;141(2):183-192.
44. Ishitsuka T, Akita H, Harashima H. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung. J Control Release. 2011;154(1):77-83.